Aumolertinib study for European patients with lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new targeted therapy, Aumolertinib, for adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has certain genetic changes (EGFR mutations). The goal is to see if the drug can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and of European descent living in a European country.
- You must have a type of lung cancer called non-small cell lung cancer that is advanced (stage IIIB/IV) or has come back after treatment, and has an EGFR mutation (ex19del, L858R, or T790M).
- You must have good organ function (kidney, liver, bone marrow) and be well enough to be up and about (ECOG score 0 or 1).
- You must not have had certain previous treatments, like a third-generation EGFR-TKI (e.g., osimertinib), or need to wait a specific time since other treatments.
- You cannot have untreated or unstable brain metastases, uncontrolled infections, heart problems, or a history of lung scarring (interstitial lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking aumolertinib (a pill that targets specific EGFR mutations) after lung cancer surgery helps prevent the cancer from coming back. It is for people with early-stage non-small cell lung cancer that has an EGFR mutation and has been completely removed.
This trial compares two targeted therapy pills, aumolertinib and osimertinib, for people with a specific EGFR mutation in advanced non-small-cell lung cancer that has spread. Both drugs are designed to block cancer growth signals. The study aims to see which one works better as a first treatment.
This study tests how a lung cancer pill called aumolertinib affects the levels of another drug (midazolam) in your body. It is for people with advanced NSCLC whose tumors have specific EGFR gene changes.
This study tests an oral targeted therapy (firmonertinib) as the first treatment for advanced EGFR-mutated non-small cell lung cancer. It uses blood tests (ctDNA) to see if the drug is working and to guide whether to continue or adjust treatment, aiming to improve outcomes while reducing side effects.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.